Since increased expression of doublecortin-like kinase 1 (DCLK1) has been reported in patients with breast cancer associated with poor prognosis, targeting DCLK1 has been proposed as a possible candidate in the field of antitumor study [147]. This evidence concerns the gene DCLK1 and breast carcinoma.